A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.

The biotechnology company on Friday said the U.K. Court of Appeal upheld the validity of its EP'949 patent. It noted the decision affirms the court's initial ruling from July 2024 that the patent is ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer says it will appeal the Aug 1 ruling to Britain’s Supreme Court. Read more at straitstimes.com. Read more at ...

London's Court of Appeal on Friday struck down a case filed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), in a bid to ...

Pfizer (PFE -1.64%) and BioNTech (BNTX -1.15%) recently fell behind in their race with Moderna (MRNA -1.60%) to develop new combination shots that could be worth billions in annual sales.

The vaccine combination pairs an experimental mRNA-based influenza vaccine candidate with Comirnaty, the FDA-approved Pfizer and BioNTech mRNA Covid-19 vaccine. The Phase 3 study enrolled more ...

This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162b2 mRNA ...

Pfizer and BioNTech miss on influenza Pfizer and BioNTech enrolled more than 8,000 healthy adults into a phase 3 trial with an mRNA vaccine candidate built to protect against influenza and COVID-19.

BioNTech's COVID-19 vaccine on one's eye, which could lead an indivual to permanent vision loss. Read on... TheHealthSite.com ...